Insider Selling: Moderna, Inc. (NASDAQ:MRNA) President Sells 20,000 Shares of Stock


Share on StockTwits

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 20,000 shares of the company’s stock in a transaction dated Monday, May 3rd. The shares were sold at an average price of $183.66, for a total value of $3,673,200.00.

Stephen Hoge also recently made the following trade(s):

  • On Friday, April 23rd, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $172.19, for a total transaction of $2,582,850.00.
  • On Tuesday, April 13th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $146.62, for a total value of $2,199,300.00.
  • On Monday, April 5th, Stephen Hoge sold 20,000 shares of Moderna stock. The stock was sold at an average price of $132.63, for a total transaction of $2,652,600.00.
  • On Wednesday, March 24th, Stephen Hoge sold 5,000 shares of Moderna stock. The shares were sold at an average price of $137.07, for a total transaction of $685,350.00.
  • On Friday, March 12th, Stephen Hoge sold 5,000 shares of Moderna stock. The stock was sold at an average price of $134.04, for a total transaction of $670,200.00.
  • On Monday, March 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $137.00, for a total transaction of $2,055,000.00.
  • On Tuesday, February 23rd, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $147.08, for a total value of $2,206,200.00.
  • On Friday, February 12th, Stephen Hoge sold 5,000 shares of Moderna stock. The shares were sold at an average price of $185.00, for a total value of $925,000.00.
  • On Wednesday, February 3rd, Stephen Hoge sold 20,000 shares of Moderna stock. The stock was sold at an average price of $157.46, for a total value of $3,149,200.00.

NASDAQ MRNA traded down $12.43 on Tuesday, hitting $173.59. 16,846,072 shares of the company traded hands, compared to its average volume of 11,744,357. The business’s 50 day moving average price is $151.16 and its 200-day moving average price is $132.68. Moderna, Inc. has a 52-week low of $46.13 and a 52-week high of $189.26. The company has a current ratio of 2.43, a quick ratio of 2.43 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $69.53 billion, a price-to-earnings ratio of -107.15, a P/E/G ratio of 0.53 and a beta of 1.73.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.44). Moderna had a negative return on equity of 28.11% and a negative net margin of 242.73%. The company had revenue of $570.80 million during the quarter, compared to the consensus estimate of $279.41 million. During the same period last year, the business earned ($0.37) EPS. The firm’s quarterly revenue was up 3948.2% compared to the same quarter last year. As a group, sell-side analysts predict that Moderna, Inc. will post -1.5 earnings per share for the current year.

A number of equities analysts have issued reports on MRNA shares. Oppenheimer boosted their price objective on shares of Moderna from $178.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, February 1st. Morgan Stanley reduced their target price on shares of Moderna from $215.00 to $201.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 4th. Wells Fargo & Company lifted their target price on shares of Moderna from $129.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, February 1st. Barclays upped their price target on Moderna from $169.00 to $178.00 in a research note on Friday, February 26th. Finally, Bank of America reiterated a “sell” rating and set a $140.00 price objective on shares of Moderna in a research note on Friday, February 26th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $152.22.

Large investors have recently bought and sold shares of the business. Jeppson Wealth Management LLC purchased a new stake in shares of Moderna during the third quarter worth about $33,000. Eudaimonia Partners LLC bought a new stake in Moderna in the third quarter worth $49,000. Mercer Global Advisors Inc. ADV raised its stake in Moderna by 60.8% during the third quarter. Mercer Global Advisors Inc. ADV now owns 6,990 shares of the company’s stock valued at $495,000 after purchasing an additional 2,643 shares in the last quarter. Virtu Financial LLC bought a new position in Moderna during the third quarter valued at $304,000. Finally, Strs Ohio grew its stake in shares of Moderna by 14.3% in the 3rd quarter. Strs Ohio now owns 11,747 shares of the company’s stock worth $831,000 after buying an additional 1,470 shares in the last quarter. 51.21% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.

Further Reading: Day Trading – Risk Worth the Reward?

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.